- Home
- JTAI vs CVKD Comparison
JTAI vs CVKD Comparison
Compare JTAI & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JTAI | CVKD |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 20.7M |
| IPO Year | N/A | 2023 |
Fundamental Metrics
Financial Performance| Metric | JTAI | CVKD |
|---|---|---|
| Price | $1.44 | $11.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $11.00 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 101.5K | 43.2K |
| Earning Date | 11-14-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $10,584,279.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $433.36 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.40 | $8.12 |
| 52 Week High | $11.77 | $22.90 |
Technical Indicators
Market Signals| Indicator | JTAI | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 31.89 | 51.02 |
| Support Level | $1.55 | $9.55 |
| Resistance Level | $1.69 | $12.00 |
| Average True Range (ATR) | 0.15 | 0.91 |
| MACD | 0.02 | 0.25 |
| Stochastic Oscillator | 5.87 | 74.23 |
Price Performance
Historical ComparisonAbout JTAI Jet.AI Inc.
Jet AI Inc is principally involved in the sale of jet cards, which enable holders to use certain aircraft owned, leased by, arranged, and/or managed by Jet Token and others at agreed-upon rates, as well as the sale of fractional interests in aircraft; and the operation of a proprietary booking platform, which functions as a prospecting and quoting platform to arrange private jet travel with third party carriers as well as through Jet Token's leased and managed aircraft.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.